Short answer
Replimune Group, Inc. (REPL) filed an 8-K current report with the SEC on August 7, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). FDA accelerated approval for TUDRIQEV (RP1) plus nivolumab in advanced unresectable cutaneous melanoma.
Replimune Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA accelerated approval for TUDRIQEV (RP1) plus nivolumab in advanced unresectable cutaneous melanoma
- Indication targets adults progressing after anti-PD-1 antibody-based treatment
- Continued approval contingent on confirmatory trials verifying clinical benefit
- Approval creates a commercial pathway while introducing regulatory risk if follow-up benefit is unconfirmed
Item EX-99.1 · Exhibit EX-99.2
- FDA accelerated approval for TUDRIQEV plus nivolumab in unresectable advanced melanoma after anti-PD-1 progression
- IGNYTE efficacy population: 24.2% objective response rate and 14.1-month median response duration among 91 patients
- Broad label includes patients with Stage 4 disease, PD-L1-negative tumors, lung or liver lesions, and prior adjuvant treatment
- Confirmatory Phase 3 IGNYTE-3 required to verify clinical benefit and preserve continued approval
- Serious adverse reactions occurred in 35% of 140 patients; permanent discontinuation occurred in 2.9%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Replimune Group, Inc. 8-K filings
Get the next REPL 8-K as it lands
Follow REPL for push alerts, or ask the research agent what this filing means.